TY  - JOUR
AU  - Paz-Ares, Luis G.
AU  - Altug, Sedat.
AU  - Vaury, Alexandra T.
AU  - Jaime, Jesús C.
AU  - Russo, Francesca.
AU  - Visseren-Grul, Carla.
PY  - 2010
DO  - 10.1186/1471-2407-10-85
UR  - http://hdl.handle.net/10668/347
T2  - BMC Cancer
AB  - BACKGROUND: To improve the efficacy of first-line therapy for advanced non-small cell lung cancer (NSCLC), additional maintenance chemotherapy may be given after initial induction chemotherapy in patients who did not progress during the initial...
LA  - en
PB  - BioMed Central
KW  - Carcinoma de Pulmón de Células no Pequeñas
KW  - Cisplatino
KW  - Antineoplásicos
KW  - Ensayos Clínicos Fase III como Asunto
KW  - Medical Subject Headings::Diseases::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms::Bronchial Neoplasms::Carcinoma, Bronchogenic::Carcinoma, Non-Small-Cell Lung
KW  - Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Clinical Protocols::Antineoplastic Protocols::Antineoplastic Combined Chemotherapy Protocols
KW  - Medical Subject Headings::Chemicals and Drugs::Inorganic Chemicals::Chlorine Compounds::Cisplatin
KW  - Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Clinical Trials as Topic::Clinical Trials, Phase III as Topic
TI  - Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer.
TY  - research article
ER  -